Substance / Medication

Interferon alfa-2b

Overview

Active Ingredient
interferon alfa-2b
RxNorm CUI
5880

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

221 trials linked to this intervention

221
Total Trials
21
Recruiting
81
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and safety of ropeginterferon alfa-2b in the treatment of polycythemia vera: a systematic review with single arm meta-analysis.
Nada Eman Ayman, Elfagieh Mohamed Abdelhalim, Abdelsalam Fares et al. · Ann Hematol · 2025
PMID: 41238945Meta-AnalysisFull text (PMC)
Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.
Poynard T, McHutchison J, Davis G L et al. · Hepatology · 2000
PMID: 11050066Meta-Analysis
Neutrophil/lymphocyte ratio identifies low-risk polycythaemia vera patients for early Ropeginterferon alfa-2b therapy.
Barbui Tiziano, Carobbio Alessandra, Guglielmelli Paola et al. · Br J Haematol · 2024
PMID: 39375955RCT
Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684.
Kirkwood J M, Strawderman M H, Ernstoff M S et al. · J Clin Oncol · 2023
PMID: 36649675RCT
Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C.
Hsu Shih-Jer, Yu Ming-Lung, Su Chien-Wei et al. · J Formos Med Assoc · 2021
PMID: 33077341RCT
HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b.
Ma Hui, Yang Rui-Feng, Li Xiao-He et al. · Chin Med J (Engl) · 2016
PMID: 27625094RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Interferon alfa-2b (substance)
SNOMED CT
386915008
UMLS CUI
C0021735
RxNorm CUI
5880

Clinical Data

This intervention maps to 20 entities in the Healos knowledge graph.

20
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
221
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.